PAVmed Inc. beat EPS estimates 41% of the time across 17 reported quarters (7 beats, 10 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.66 | — | — | Miss |
| Q12026 FY2026 | $-0.80 | $-4.47 | -458.8% | Miss |
| Q1 FY2026 | — | — | — | Miss |
| 2026-03-24 | $-4.50 | — | — | Miss |
| Q3 FY2025 | $-6.01 | $-8.41 | -39.9% | Miss |
| Q2 FY2025 | $-0.25 | $-0.05 | +80.0% | Beat |
| Q1 FY2025 | $-0.29 | $-0.07 | +75.9% | Beat |
| 2025-03-25 | $-0.40 | $-0.06 | +85.0% | Beat |
| Q3 FY2024 | $-1.30 | $-0.54 | +58.5% | Beat |
| Q2 FY2024 | $-1.45 | $-0.84 | +42.1% | Beat |
| Q1 FY2024 | $-1.67 | $-0.99 | +40.7% | Beat |
| 2024-03-26 | $-1.89 | $-1.33 | +29.6% | Beat |
Back to PAVM overview · PAVM holders · PAVM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.